Protocol Ledger

NCT03393000 · Phase III · TERMINATED

Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Interventional Phase III clinical trial protocol NCT03393000 sponsored by Diffusion Pharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-01-16 Enrollment: 19 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03393000
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)19 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03393000
Protocol FieldVerified Registry Value
NCT IdentifierNCT03393000
Consolidated Lead SponsorDiffusion Pharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment19 participants (ACTUAL)
Registered Start Date2018-01-16
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03393000
Hospital Research SiteLocationSite Profile
Abbott-Northwestern HospitalMinneapolis, MNOpen Hospital Dossier ->
Mount Sinai Hospital and Icahn School of MedicineNew York, NYOpen Hospital Dossier ->
Providence Portland Medical CenterPortland, OROpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI